All Pluvicto (lutetium Lu 177 vipivotide tetraxetan) articles
-
News
Novartis opens third US radioligand manufacturing facility
California site adds to the Swiss pharma company’s operations in Florida and Texas.
-
ArticleThe future of targeted alpha therapy development and manufacture
Following the first industrial-scale facility for targeted alpha therapy (TAT) production in Europe beginning construction, in this exclusive Q&A, Julien Dodet, CEO of Orano Med, elaborates on the key trends in radioligand therapeutics and why TATs hold significant advantages as cancer treatments.